Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Propionyl carnitine

Drug Profile

Propionyl carnitine

Alternative Names: Dromos; Levocarnitine proprionate; Levocarnitine proprionate hydrochloride; PLC; Propionyl-L-carnitine; Propionyl-L-carnitine HCl; Propionyl-L-carnitine hydrochloride; ST 261

Latest Information Update: 28 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sigma-tau SpA
  • Developer Lees Pharmaceutical Holdings; sigma-tau SpA
  • Class Anti-ischaemics; Heart failure therapies; Ischaemic heart disorder therapies; Small molecules; Trimethyl ammonium compounds; Vascular disorder therapies; Vitamins
  • Mechanism of Action Free radical scavengers; Pyruvate dehydrogenase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Peripheral arterial occlusive disorders
  • Discontinued Angina pectoris; Heart failure; Kidney disorders; Myocardial ischaemia; Ulcerative colitis

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Peripheral-arterial-occlusive-disorders(In volunteers) in China (PO, Tablet)
  • 24 Jun 2018 Biomarkers information updated
  • 02 Apr 2012 sigma-tau plans a phase III trial for Ulcerative colitis in Austria, France, Germany, Hungary, Latvia, Lithuania, Poland and Spain (NCT01567956)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top